Showing 3981-3990 of 5646 results for "".
- Bausch + Lomb and Heidelberg Engineering Introduce SeeLuma Fully Digital Surgical Visualization Platformhttps://modernod.com/news/bausch-lomb-and-heidelberg-engineering-introduce-seeluma-fully-digital-surgical-visualization-platform/2481528/Bausch + Lomb and Heidelberg Engineering announced the introduction of the SeeLuma Fully Digital Surgical Visualization Platform, which is designed to p
- Researchers Explain How Reading Might Contribute to Myopiahttps://modernod.com/news/researchers-explain-how-reading-might-contribute-to-myopia/2481520/Researchers at the State University of New York (SUNY) are publishing a paper explaining how reading might contribute to myopia. In a paper that will be published in the Journal of Vision, scientists demonstrate that the images formed by our eyes during reading lack
- NEI: Extremely Rare Gene Variants Point to a Potential Cause of AMDhttps://modernod.com/news/nei-extremely-rare-gene-variants-point-to-a-potential-cause-of-amd/2481519/A study from the National Eye Institute (NEI) identified rare genetic variants that could point to one of the general mechanisms driving age-related macular degeneration (AMD). The variants generate malformed proteins that alter the stability of the membrane attack complex (MAC), which may drive
- Celanese Enters Agreement with Glaukos for Sustained Release Glaucoma Treatmenthttps://modernod.com/news/celanese-enters-agreement-with-glaukos-corporation-for-sustained-release-glaucoma-treatment/2481514/Celanese announced that it has entered into an agreement with Glaukos Corporation to supply its VitalDose Drug Delivery Platform for use as a component in Glaukos’ iDose TR, a micro-invasive intraocular implant designed to lower IOP in patients with primary open-ang
- Startup Vedere Bio II Shuts Down After Preclinical Studies Fall Shorthttps://modernod.com/news/startup-vedere-bio-ii-shuts-down-after-preclinical-studies-fall-short/2481512/About 2 years after its launch, gene therapy start-up Vedere Bio II is shutting down. The decision comes after preclinical studies did not meet targets. The announcement was made from the company’s chairman Kevin Bitterman and CEO Cyrus Mozayeni. “We had a bold mission, to d
- First Myopia Action Month Announced for Septemberhttps://modernod.com/news/first-myopia-action-month-announced-for-september/2481510/Myopia Profile announced its launch of Myopia Action Month to channel myopia awareness into action. Taking place in September, the inaugural event is designed to bring 4 weeks of global education, industry collaboration, and encouragement to ECPs to empower them to take effect
- Aviceda Announces 3 Presentations on AVD-104, its Lead Glyco-mimetic Nanoparticle, As Treatment for GA at ARVOhttps://modernod.com/news/aviceda-announces-3-presentations-on-avd-104-its-lead-glyco-mimetic-nanoparticle-as-treatment-for-ga-at-arvo/2481507/Aviceda Therapeutics announced its upcoming oral and poster presentations at the 2023 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans, April 23-27, 2023. Detailed results from each of these three studies will be reported at the conference.
- Kala Pharmaceuticals Appoints Francis Mah, MD, as Chief Medical Advisorhttps://modernod.com/news/kala-pharmaceuticals-appoints-francis-mah-md-as-chief-medical-advisor/2481501/Kala Pharmaceuticals announced the appointment of Francis Mah, MD, as Chief Medical Advisor. In this new role, Dr. Mah will provide support for Kala’s clinical development and medical activities and will play a key role in interactions with eye care professionals. Dr. Mah will serve in
- Andreas C. Kühnel Appointed as Geschäftsführer Managing Director at VSY Biotechnologyhttps://modernod.com/news/andreas-c-kuhnel-appointed-as-geschaftsfuhrer-managing-director-at-vsy-biotechnology/2481500/VSY Biotechnology has announced the appointment of Andreas Christoph Kühnel as its new Managing Director. In this new role, Mr. Kühnel will be responsible for developing and expanding VSY Biotechnology’s operations on a global scale. Mr. Kühnel brings expertise and
- World Council of Optometry and Alcon to Launch “WCO Alcon Dry Eye Wheel” Tool for Dry Eye Diseasehttps://modernod.com/news/world-council-of-optometry-and-alcon-to-launch-wco-alcon-dry-eye-wheel-tool-for-dry-eye-disease/2481496/The World Council of Optometry (WCO) and Alcon invite eye care professionals worldwide to the launch of a new tool to help with the diagnosis and treatment of dry eye disease. Registration is now open for the May 9 “Dry Eye Spotlight 4: WCO Alcon Dry Eye Wheel” webinar, the